Led by researchers at the University of Laval in Canada, the study found that mice with increased levels of cannabinoid ...

Researchers from Washington University School of Medicine and Stanford University have developed a compound that simulates a ...

Evidence is stacking up about the influence of cannabinoids on cardiovascular disease, and newer, synthetic options are ...

Researchers create a cannabis-derived compound that relieves pain without the risk of addiction or mind-altering effects.

POTOMAC, MD / ACCESS Newswire / March 20, 2025 / IGC Pharma, Inc. ("IGC", or the "Company") (NYSE American:IGC) today ...

The protein, called cannabinoid receptor type 1 (CB1), is part of the blood-brain barrier, the dynamic structure that protects the brain by regulating the passage of molecules between the ...

Allied Market Research published a report, titled, "Cannabinoid Based Drug Discovery and Development Market by Receptor Target (CB1 Receptor, CB2 Receptor), by End User (Pharmaceutical Companies, ...

The drug, known as VIP36, targets the body’s cannabinoid receptor type 1 (CB1). It was found to be effective in three different animal models for pain and does not appear to cause the harmful side ...

They bind to a receptor, called cannabinoid receptor one (CB1), on the surface of brain cells and on pain-sensing nerve cells throughout the body. Working with collaborators at Stanford University, co ...

This achievement leverages the pain-relieving properties of cannabis without inducing mind-altering side effects. The ...

“The protein, called cannabinoid receptor type 1 (CB1), is part of the blood-brain barrier, the dynamic structure that protects the brain by regulating the passage of molecules between the blood ...